利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.042 秒)

    Coating for optical fibers
    94.
    发明授权
    Coating for optical fibers 失效
    光纤涂层

    公开(公告)号：US06731849B1

    公开(公告)日：2004-05-04

    申请号：US10444904

    申请日：2003-05-22

    申请人： Bawa Singh ,  Nalin Kumar ,  Vipulkumar Patel ,  Krishna Linga ,  Ali Ouali

    发明人： Bawa Singh ,  Nalin Kumar ,  Vipulkumar Patel ,  Krishna Linga ,  Ali Ouali

    IPC分类号： G02B602

    CPC分类号： G02B6/2558 ,  C03C25/226 ,  C23C14/3407 ,  C23C14/352 ,  C23C14/562 ,  G02B6/02395 ,  G02B6/25 ,  Y10T428/2964

    摘要： An improved coating for optical fibers is described. The present invention is a dimensionally precise and uniform coating with low-porosity. The improved coating is applied via sputtering within a vacuum chamber. Environmental conditions are monitored within a cylindrical magnetron during sputtering. Sputtering is adjusted or temporarily ceased when environmental conditions approach a damage threshold. Sputtered particles within a plasma cloud are dimensionally similar and adhere to an optical fiber in a volume efficient arrangement forming a more precise, denser, and more adherent coating. Embodiments of the present invention provide improved pull strength by compressively constraining the optical fiber within the coating and by closing microcracks.

    摘要翻译： 描述了一种改进的光纤涂层。 本发明是具有低孔隙率的尺寸精确且均匀的涂层。 改进的涂层通过溅射在真空室内进行。 在溅射期间，在圆柱形磁控管内监测环境条件。 当环境条件接近损伤阈值时，溅射被调整或暂时停止。 等离子体云中的溅射颗粒在尺寸上相似并且以体积有效的布置粘附到光纤上，形成更精确，更致密和更粘附的涂层。 本发明的实施例通过在涂层内压缩约束光纤并且通过闭合微裂纹来提供改进的拉伸强度。

    Chemical compounds
    95.
    发明申请
    Chemical compounds 失效
    化合物

    公开(公告)号：US20060074111A1

    公开(公告)日：2006-04-06

    申请号：US10518778

    申请日：2003-06-18

    申请人： Paul Beswick ,  John Harling ,  Savvas Kleanthous ,  Millard Lambert ,  Vipulkumar Patel ,  Juliet Simpson

    发明人： Paul Beswick ,  John Harling ,  Savvas Kleanthous ,  Millard Lambert ,  Vipulkumar Patel ,  Juliet Simpson

    IPC分类号： C07D213/55 ,  A61K31/44 ,  A61K31/195

    CPC分类号： C07D213/74 ,  C07C217/58 ,  C07C217/80 ,  C07C233/18 ,  C07C255/58 ,  C07C311/08 ,  C07C311/29 ,  C07C323/25 ,  C07C2601/02 ,  C07D239/42 ,  C07D241/20

    摘要： A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, Wherein: R1 and R2 are independently hydrogen or C1-3 alkyl; X represents a bond, CH2 or O; R3 and R4 are independently hydrogen, C1-6 alkyl, OCH3, CF3, allyl or halogen; X1 is CH2, SO2, or CO; R5 is —C1-6 alkyl (optionally substituted by C1-6alkoxy or C1-6alkylthio), —C2-6 alkenyl, —C0-6 alkyl phenyl (wherein the phenyl is optionally substituted by one or more CF3, halogen, C1-3 alkyl, C1-3 alkoxy), —COC1-6 alkyl, SO2C1-6 alkyl; R6 is phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C1-6 alkyl, halogen, —OC1-6 alkyl, —SO2C1-3 alkyl, phenyl (optionally substituted by one or more groups selected from halogen, CF3, C1-3 alkyl, OC1-3 alkyl, acetyl, CN).

    摘要翻译： 式（I）化合物或其药学上可接受的盐，溶剂化物或可水解的酯，其中R 1和R 2独立地是氢或C 1 -3 烷基; X表示键，CH 2或O; R 3和R 4独立地是氢，C 1-6烷基，OCH 3，CF 3， 3，烯丙基或卤素; X 1是CH 2，SO 2，或CO; R 5是-C 1-6 - 烷基（任选被C 1-6烷氧基或C 1-6 - 烷基取代） 烷硫基），-C 2-6亚烯基，-C 0-6烷基苯基（其中苯基任选被一个或多个CF 3取代） 卤素，C 1-3烷基，C 1-3烷氧基），-COC 1-6烷基，SO 3 - 2个C 1-6烷基; R 6是苯基或含有1,2或3个N原子的6元杂芳基，其中苯基或杂芳基任选被1,2或3个选自C

    Benzamide derivatives as thrombin inhibitors
    97.
    发明授权
    Benzamide derivatives as thrombin inhibitors 失效
    苯甲酰胺衍生物作为凝血酶抑制剂

    公开(公告)号：US06326386B1

    公开(公告)日：2001-12-04

    申请号：US09678610

    申请日：2000-10-04

    申请人： Nigel Stephen Watson ,  Martin Pass ,  Vipulkumar Patel

    发明人： Nigel Stephen Watson ,  Martin Pass ,  Vipulkumar Patel

    IPC分类号： C07D21302

    CPC分类号： C07D213/74 ,  A61K31/4409 ,  A61K31/4439 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

    摘要： The invention relates to a novel class of amide derivatives which act as thrombin inhibitors as described by formula (I), where R1 and R2, independently represent a group (a) or R1 and R2 together form a C3-7 heterocycloalkyl or heterocycloalkenyl group which may be optionally substituted by C1-6 alkyl, C1-4 alkoxy, halogen, carboxylic acid or a C1-4 carboxylic acid ester group; R3 represents hydrogen, C1-3 alkyl, halogen, or C1-2 alkoxy; R4, R5 and R6 independently represent hydrogen, or halogen; R7 represents hydrogen or C1-6 alkyl; R8 represents hydrogen, C3-7 cycloalkyl, C3-7 cycloalkenyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkenyl, aryl or heteroaryl, which groups are optionally substituted by one or more groups selected from halogen, hydroxy, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 acyloxy, NR9R10, NHCOR11, NHSO2R12, COR13, CO2R14, CONR15R16, and SO2NHR17; X represents a bond, a C1-6 alkyl chain, or a C3-6 alkenyl chain, where one or two nitrogen, oxygen, or sulfur atoms may be optionally contained within each chain, and the chains are optionally substituted by one or more groups selected from halogen, hydroxy, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 acyloxy, NR9R10, NHCOR11, NHSO2R12, COR13, CO2R14, CONR15R16, and SO2NHR17; R9-R17 represent hydrogen, C1-6 alkyl, or R9 and R10 or R15 and R16 form a C3-7 heterocycloalkyl ring, or R12 additionally may represent trifluoromethyl; and pharmaceutically acceptable derivatives or solvates thereof, to processes for their preparation; and their use in the treatment of clinical conditions susceptible to amelioration by administration of a thrombin inhibitor.

    摘要翻译： 本发明涉及作为如式（I）所述的凝血酶抑制剂的新一类酰胺衍生物，其中R 1和R 2独立地表示基团（a）或R 1和R 2一起形成C 3-7杂环烷基或杂环烯基，其中 可以任选地被C 1-6烷基，C 1-4烷氧基，卤素，羧酸或C 1-4羧酸酯基取代; R 3表示氢，C 1-3烷基，卤素或C 1-2烷氧基; R4，R5和R6独立地表示氢或卤素; R 7表示氢或C 1-6烷基; R8表示氢，C3-7环烷基，C3-7环烯基，C3-7杂环烷基，C3-7杂链烯基，芳基或杂芳基，这些基团任选被一个或多个选自卤素，羟基，CN，C 1-6烷基的基团取代 ，C 1-6烷氧基，C 1-6酰氧基，NR 9 R 10，NHCOR 11，NHSO 2 R 12，COR 13，CO 2 R 14，CONR 15 R 16和SO 2 NHR 17; X表示键，C 1-6烷基链或C 3-6烯基链，其中每个链中可任选地含有一个或两个氮，氧或硫原子，并且该链任选被一个或多个基团取代 选自卤素，羟基，CN，C 1-6烷基，C 1-6烷氧基，C 1-6酰氧基，NR 9 R 10，NHCOR 11，NHSO 2 R 12，COR 13，CO 2 R 14，CONR 15 R 16和SO 2 NHR 17; R9-R17表示氢，C1-6烷基或R9，R10或R15和R16形成C